Skip to main content
Erschienen in: Strahlentherapie und Onkologie 5/2016

29.02.2016 | Original Article

Seed loss in prostate brachytherapy

Operator dependency and impact on dosimetry

verfasst von: Nancy El-Bared, M.D., Natanel Sebbag, Dominic Béliveau-Nadeau, M.Sc., Yannick Hervieux, M.Sc., Renée Larouche, M.Sc., Daniel Taussky, M.D., Guila Delouya, M.D., M.Sc.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of our study was to review seed loss and its impact on dosimetry as well as the influence of the treating physician on seed loss and dosimetry in patients treated with prostate brachytherapy using permanent loose 125I implant.

Patients and methods

We analyzed 1087 consecutive patients treated by two physicians between July 2005 and April 2015 at a single institution. Pelvic fluoroscopic imaging was done 30 days post implant and a chest X-ray when seed loss was observed.

Results

Seed loss occurred in 19.4 % of patients: in 20.0 % of implants done by the most experienced physician and in 17.2 % by the less experienced physician (p = 0.4) and migration to the thorax occurred in 5.9 % (6.9 vs. 2.2 %, p = 0.004). The mean seed loss rate was 0.57 % [standard deviation (SD) 1.39] and the mean rate of seeds in the thorax was 0.14 % (SD 0.65). The most experienced physician had a higher mean number of seeds lost: 0.36 versus 0.25 (p = 0.055), and a higher mean number of seed migration to the thorax: 0.1 versus 0.02 (p < 0.001). When at least one seed was lost, a decrease of 4.2 Gy (p < 0.001) in the D90 and a decrease of 3.5 % (p = 0.002) in the V150 was observed.

Conclusion

We found a significant decrease in V150 and D90 with the occurrence of seed loss. Furthermore, we found a difference in seed migration among the physicians demonstrating that seed loss is operator dependant.
Literatur
1.
Zurück zum Zitat Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Seki S et al (2011) Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol 6:130CrossRefPubMedPubMedCentral Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Seki S et al (2011) Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol 6:130CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Kono Y, Kubota K, Aruga T, Ishibashi A, Morooka M, Ito K et al (2010) Swelling of the prostate gland by permanent brachytherapy may affect seed migration. Jpn J Clin Oncol 40:1159–1165CrossRefPubMed Kono Y, Kubota K, Aruga T, Ishibashi A, Morooka M, Ito K et al (2010) Swelling of the prostate gland by permanent brachytherapy may affect seed migration. Jpn J Clin Oncol 40:1159–1165CrossRefPubMed
3.
Zurück zum Zitat Zhu AX, Wallner KE, Frivold GP, Ferry D, Jutzy KR, Foster GP (2006) Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy 5:262–265CrossRefPubMed Zhu AX, Wallner KE, Frivold GP, Ferry D, Jutzy KR, Foster GP (2006) Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy 5:262–265CrossRefPubMed
4.
Zurück zum Zitat Chen WC, Katcher J, Nunez C, Tirgan AM, Ellis RJ (2012) Radioactive seed migration after transperineal interstitial prostate brachytherapy and associated development of small-cell lung cancer. Brachytherapy 11:354–358CrossRefPubMed Chen WC, Katcher J, Nunez C, Tirgan AM, Ellis RJ (2012) Radioactive seed migration after transperineal interstitial prostate brachytherapy and associated development of small-cell lung cancer. Brachytherapy 11:354–358CrossRefPubMed
5.
Zurück zum Zitat Knaup C, Mavroidis P, Esquivel C, Stathakis S, Swanson G, Baltas D et al (2012) Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys 39:3291–3298CrossRefPubMedPubMedCentral Knaup C, Mavroidis P, Esquivel C, Stathakis S, Swanson G, Baltas D et al (2012) Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys 39:3291–3298CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Beaulieu L, Archambault L, Aubin S, Oral E, Taschereau R, Pouliot J (2004) The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. Int J Radiat Oncol Biol Phys 58:1298–308CrossRefPubMed Beaulieu L, Archambault L, Aubin S, Oral E, Taschereau R, Pouliot J (2004) The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. Int J Radiat Oncol Biol Phys 58:1298–308CrossRefPubMed
7.
Zurück zum Zitat Gao M, Wang JZ, Nag S, Gupta N (2007) Effects of seed migration on post-implant dosimetry of prostate brachytherapy. Med Phys 34:471–480CrossRefPubMed Gao M, Wang JZ, Nag S, Gupta N (2007) Effects of seed migration on post-implant dosimetry of prostate brachytherapy. Med Phys 34:471–480CrossRefPubMed
8.
Zurück zum Zitat Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ (2004) Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy 3:71–77CrossRefPubMed Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ (2004) Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy 3:71–77CrossRefPubMed
9.
Zurück zum Zitat Tapen EM, Blasko JC, Grimm PD, Ragde H, Luse R, Clifford S et al (1998) Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 42:1063–1067CrossRefPubMed Tapen EM, Blasko JC, Grimm PD, Ragde H, Luse R, Clifford S et al (1998) Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 42:1063–1067CrossRefPubMed
10.
Zurück zum Zitat Fuller DB, Koziol JA, Feng AC (2004) Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy 3:10–19CrossRefPubMed Fuller DB, Koziol JA, Feng AC (2004) Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors. Brachytherapy 3:10–19CrossRefPubMed
11.
Zurück zum Zitat Hathout L, Donath D, Moumdjian C, Tetreault-Laflamme A, Larouche R, Beliveau-Nadeau D et al (2011) Analysis of seed loss and pulmonary seed migration in patients treated with virtual needle guidance and robotic seed delivery. Am J Clin Oncol 34:449–453CrossRefPubMed Hathout L, Donath D, Moumdjian C, Tetreault-Laflamme A, Larouche R, Beliveau-Nadeau D et al (2011) Analysis of seed loss and pulmonary seed migration in patients treated with virtual needle guidance and robotic seed delivery. Am J Clin Oncol 34:449–453CrossRefPubMed
12.
Zurück zum Zitat Taussky D, Moumdjian C, Larouche R, Beliveau-Nadeau D, Boudreau C, Hervieux Y et al (2012) Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy 11:452–456CrossRefPubMed Taussky D, Moumdjian C, Larouche R, Beliveau-Nadeau D, Boudreau C, Hervieux Y et al (2012) Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy 11:452–456CrossRefPubMed
13.
Zurück zum Zitat Bowes D, Gaztanaga M, Araujo C, Kim D, Parker B, Batchelar D et al (2013) A randomized trial comparing seed displacement of coated seeds to regular loose seeds at 30 days postimplant. Brachytherapy 12:362–367CrossRefPubMed Bowes D, Gaztanaga M, Araujo C, Kim D, Parker B, Batchelar D et al (2013) A randomized trial comparing seed displacement of coated seeds to regular loose seeds at 30 days postimplant. Brachytherapy 12:362–367CrossRefPubMed
14.
Zurück zum Zitat Ishiyama H, Satoh T, Kawakami S, Tsumura H, Komori S, Tabata K et al (2014) A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. Int J Radiat Oncol Biol Phys 90:134–9CrossRefPubMed Ishiyama H, Satoh T, Kawakami S, Tsumura H, Komori S, Tabata K et al (2014) A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. Int J Radiat Oncol Biol Phys 90:134–9CrossRefPubMed
15.
Zurück zum Zitat Zuber S, Weiss S, Baaske D, Schope M, Stevens S, Bodis S et al (2015) Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. Radiat Oncol 10:49CrossRefPubMedPubMedCentral Zuber S, Weiss S, Baaske D, Schope M, Stevens S, Bodis S et al (2015) Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. Radiat Oncol 10:49CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM et al (2011) American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79:335–41CrossRefPubMed Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM et al (2011) American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79:335–41CrossRefPubMed
17.
Zurück zum Zitat Shiraishi Y, Yorozu A, Ohashi T, Toya K, Saito S, Nishiyama T et al (2014) A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 90:1069–75CrossRefPubMed Shiraishi Y, Yorozu A, Ohashi T, Toya K, Saito S, Nishiyama T et al (2014) A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 90:1069–75CrossRefPubMed
18.
Zurück zum Zitat Gacci M, Serni S, Lapini A, Vittori G, Vignolini G, Nesi G et al (2008) PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy. Prostate Cancer Prostatic Dis 11:99–101CrossRefPubMed Gacci M, Serni S, Lapini A, Vittori G, Vignolini G, Nesi G et al (2008) PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy. Prostate Cancer Prostatic Dis 11:99–101CrossRefPubMed
19.
Zurück zum Zitat Nag S, Demanes DJ, Hagan M, Rivard MJ, Thomadsen BR, Welsh JS et al (2011) Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: a report from the American Society for Radiation Oncology. Pract Radiat Oncol 1:218–223CrossRefPubMedPubMedCentral Nag S, Demanes DJ, Hagan M, Rivard MJ, Thomadsen BR, Welsh JS et al (2011) Definition of medical event is to be based on the total source strength for evaluation of permanent prostate brachytherapy: a report from the American Society for Radiation Oncology. Pract Radiat Oncol 1:218–223CrossRefPubMedPubMedCentral
Metadaten
Titel
Seed loss in prostate brachytherapy
Operator dependency and impact on dosimetry
verfasst von
Nancy El-Bared, M.D.
Natanel Sebbag
Dominic Béliveau-Nadeau, M.Sc.
Yannick Hervieux, M.Sc.
Renée Larouche, M.Sc.
Daniel Taussky, M.D.
Guila Delouya, M.D., M.Sc.
Publikationsdatum
29.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 5/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-0961-4

Weitere Artikel der Ausgabe 5/2016

Strahlentherapie und Onkologie 5/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.